Chandra Bhagat Pharma Reports Half-Year Financial Results for September 2025

Chandra Bhagat Pharma Limited , a pharmaceutical company listed on the BSE (Scrip Code: 542934), has released its unaudited financial results for the half year ended September 30, 2025. The company's Board of Directors approved these results during a meeting held on November 13, 2025.

Financial Highlights

Key Points

• The board meeting commenced at 5:00 PM and concluded at 7:30 PM at the company's registered office in Mumbai.
• The financial results were reviewed by A Y & Company, Chartered Accountants, who issued a limited review report.
• The review was conducted in accordance with the Standard on Review Engagements (SRE) 2410.

Insider Trading Regulations

In compliance with SEBI regulations and the company's code of conduct for prohibition of insider trading:

• The "Trading Window" for the company's shares will reopen 48 hours after the announcement of the financial statement.
• This applies to Directors, Key Managerial Personnel, Designated Employees, and Connected Persons as defined in the company's insider trading code.

Auditor's Statement

A Y & Company, the company's auditors, stated in their review report:

"Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Standalone financial results... contains any material misstatement."

The financial results and the limited review report have been submitted to the BSE Limited in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investors and stakeholders are advised to consider these results in the context of the overall market conditions and the pharmaceutical sector's performance.